Navigation Links
XELR8 Holdings Announces Fiscal 2007 Financial Results

- Company Reports Record 2007 Revenue of $4.9 Million, an Increase of 126%

- - Removal of the Going Concern Qualification by its Independent Registered

Public Accountants -

- Management to Host Conference Call Today at 4:15 p.m. ET -

DENVER, March 26 /PRNewswire-FirstCall/ -- XELR8 Holdings, Inc. (Amex: BZI), a provider of functional foods, beverages and nutritional supplements, today announced its financial results for the twelve months ended December 31, 2007.

Financial and operational highlights for Fiscal 2007:

-- Revenues increased 126% over prior year period

-- Gross profit margin was 72%, up 800 basis points from 64% in 2006

-- Bazi(TM) represented 83% of revenues in 2007, major growth component

-- Working capital of $2.1 million as of December 31, 2007

Total revenue for the fiscal year ended December 31, 2007 was $4.9 million, a 126% increase compared to total revenue of $2.1 million for the fiscal year ended December 31, 2006. Gross profit grew to $3.5 million for the fiscal 2007, up 153% from $1.4 million in the prior year period. Net loss for the year ended December 31, 2007, decreased 31% to $3.2 million, or $0.23 per share, compared to a loss of $4.7 million, or $0.48 per share, in the prior year.

The Company's balance sheet continues to remain strong. As of December 31, 2007, cash and cash equivalents were $2.25 million, excluding the proceeds from the February 2008 financing. Total shareholders' equity at the end of fiscal 2007 was $2.22 million and the Company remains debt free. As a result of the improved operating performance and the additional financing, the Company's Independent Registered Public Accountants have removed the going concern qualification from their report.

"I am pleased with XELR8's performance in fiscal 2007," said John Pougnet, XELR8 CEO. "Fiscal 2007 was a pivotal year for XELR8, especially with the launch of our lead product Bazi, in January 2007, which has become a dominant part of our revenues as well as our anchor for future growth."

Mr. Pougnet continued, "During fiscal 2007 we built an excellent foundation for marketing Bazi, ending the year with 8,416 participants nationwide. We have begun leveraging our distributor base in fiscal 2008 through various means that we believe will not only assist them in building their current clientele, but also enhance our network by finding more distributors to broaden our reach. In addition to our recent distributor convention in Las Vegas, which was a resounding success, we have begun to offer new incentives and bonus features as well as incorporate regional "Go Diamond" events, to be hosted in six major cities nationwide in the coming weeks. It is events like these that enable us to keep in touch with our distributors and not only help in their growth, but also learn and grow from their success stories that we can then share network-wide."

"We are focused on attaining profitability and are getting closer to that goal daily. Fortunately, the Company is well capitalized and can undertake expenditures that will not only contribute ultimately to profitability but also strengthen our distribution network leading to broader acceptance of our products and, in particular, Bazi," concluded Mr. Pougnet.

There will be a conference call today at 4:15 p.m. ET with the investment community, featuring John Pougnet, Chief Executive Officer of XELR8 Holdings, Inc. Interested parties may participate in the call by dialing 877-407-8293; international callers dial 201-689-8349. In addition, a replay of the conference call will be available approximately two hours after the call has ended. The replay can be accessed at: and will be archived for 30 days.

About XELR8 Holdings, Inc.

XELR8 Holdings, Inc. is a provider of nutritional foods and beverages designed to help enhance physical health and overall performance. XELR8 has developed a comprehensive line of nutritional supplements and functional foods designed in systems that are easy to take, simple to understand, and conveniently fit within a lifestyle. These include the Company's Eat/Drink/Snack System; Peak Performance System; and its newest market entry, Bazi(TM), a powerful, concentrated, antioxidant (Vitamins A, C & E) nutritional drink packed with eight different super fruits and berries, including the Chinese jujube plus 12 vitamins and 68 minerals, providing all the daily vitamins and minerals you need in a single, convenient, one-ounce shot.

XELR8's commitment to quality, science and research has earned the Company a loyal following of over 350 world-class athletes and an elite list of endorsers, such as 3-time World Series Champion Curt Schilling, five-time Cy Young Award Winner Randy Johnson; Super Bowl Champions Mike Alstott and Lawyer Milloy; professional football star Cadillac Williams; Olympians Briana Scurry and Caroline Lalive; Stanley Cup Winner Blake Sloan; and PGA Tour Professional Tom Pernice, Jr. XELR8 products are only available through independent distributors located throughout the nation. For more information about XELR8, please visit or .

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including prospects for XELR8's distribution network. Actual results may differ from those discussed in such forward-looking statements. These forward-looking statements include risks and uncertainties that include the Company's ability to attract and retain distributors; changes in demand for the Company's products; changes in the level of operating expenses; changes in general economic conditions that impact consumer behavior and spending; product supply; the availability, amount, and cost of capital for the Company; and the Company's use of such capital. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006 and all subsequent filings. Certain statements in this release regarding the Company's agreements are in accordance with the guidelines established by the Federal Trade Commission for endorsements in advertising.


John Pougnet, CEO Stephen D. Axelrod, CFA

XELR8 Holdings, Inc. Alisa Steinberg (Media)

(303) 316-8577 Wolfe Axelrod Weinberger Assoc. LLC (212) 370-4500



For the Years Ended December 31, 2007 and 2006

2007 2006


Current assets:

Cash and cash equivalents $2,245,858 $76,147

Accounts receivable, net of

allowance for doubtful accounts

of $12,231 and $10,706,

respectively 7,460 4,785

Inventory, net of allowance for

obsolescence of $189,403 and

$41,655, respectively 370,843 411,364

Prepaid expenses and other

current assets 329,015 259,292

Total current assets 2,953,176 751,588

Intangible assets, net 17,959 11,212

Property and equipment, net 81,405 123,943

Deferred offering and loan costs - 133,889

Total assets $3,052,540 $1,020,632



Current liabilities:

Accounts payable and accrued

expenses $832,697 $1,160,916

Short-term note payable - 250,000

Total Liabilities 832,697 1,410,916

Commitments and Contingencies (Note 7)


Preferred stock, authorized 5,000,000

shares, $.001 par value, none issued

or outstanding - -

Common stock, authorized 50,000,000

shares, $.001 par value, 15,197,170

and 10,097,170 shares issued and

outstanding, respectively 15,197 10,097

Additional paid in capital 22,696,657 16,849,900

Accumulated (deficit) (20,492,011) (17,250,281)

Total shareholders' equity

(deficit) 2,219,843 (390,284)

Total liabilities and

shareholders' equity $3,052,540 $1,020,632



For the Years Ended December 31, 2007 and 2006

2007 2006

Net revenue $4,853,046 $2,148,420

Cost of goods sold 1,380,663 775,762

Gross profit 3,472,383 1,372,658

Operating expenses:

Selling and marketing expenses 3,180,392 2,626,613

General and administrative expenses 3,107,469 3,275,689

Research and development expenses 17,828 73,921

Depreciation and amortization 58,033 66,333

Total operating expenses 6,363,722 6,042,556

Net (loss) from operations (2,891,339) (4,669,898)

Other income (expense)

Interest income 87,646 34,337

Gain on disposal of asset 1,500 -

Interest (expense) (439,537) (33,888)

Total other income (expense) (350,391) 449

Net (loss) $(3,241,730) $(4,669,449)

Net (loss) per common share

Basic and diluted net (loss) per share $(0.23) $(0.48)

Weighted average common shares

outstanding, basic and diluted 13,951,691 9,714,021



For the Years Ended December 31, 2007 and 2006

2007 2006

Cash flows from operating activities:

Net income (loss) $(3,241,730) $(4,669,449)

Adjustments to reconcile

Depreciation and amortization 58,033 66,333

(Gain) on sale of equipment (1,500) -

Stock and stock options issued for

services 1,372,408 859,489

Interest expense and amortization

related to bridge loan financing 428,889 -

Change in allowance for doubtful

accounts 1,525 5,243

Change in allowance for inventory

obsolescence 147,748 24,776

Change in allowance for product

returns 30,866 25,013

Changes in assets and liabilities:

Accounts receivable (4,200) (1,270)

Inventory (107,227) 106,609

Other current assets (69,723) (88,679)

Accounts payable and accrued

expenses 205,915 679,907

Net cash (used) by operating

activities (1,178,996) (2,992,028)

Cash flows from investing activities:

Proceeds from maturity of investments - 110,000

Proceeds from sale of equipment 1,500 -

Capital expenditures (22,242) (71,846)

Net cash (used) provided by

investing activities (20,742) 38,154

Cash flow from financing activities:

Proceeds from bridge loan financing 250,000 250,000

Repayments of bridge financing (500,000) -

Issuance of common stock, net of

offering costs 3,619,449 -

Deferred offering costs - (25,000)

Net cash provided by financing

activities 3,369,449 225,000

NET INCREASE (DECREASE) IN CASH 2,169,711 (2,728,874)


OF THE PERIOD 76,147 2,805,021


THE PERIOD $2,245,858 $76,147


Cash paid for interest $13,425 $-

Stock issued for satisfaction of

accrued compensation expense $540,000 $-

Deferred offering costs applied

against proceeds from offering $25,000 $-

SOURCE XELR8 Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007
2. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
3. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
4. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
5. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
6. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
7. Platinum Underwriters Holdings, Ltd. to Report Third Quarter 2007 Results on October 23, 2007
8. Air Methods Completes Acquisition of FSS Airholdings, Inc., Parent Company of CJ Systems Aviation Group, Inc.
9. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2007 Results
10. NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call
11. HMS Holdings Corp. Hosts Third Quarter 2007 Financial Teleconference and Presentation
Post Your Comments:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
Breaking Medicine Technology: